Federal Register / Vol. 82, No. 173 / Friday, September 8, 2017 / Notices 42559 

go/connectpro_overview. FDA has 

verified the Web site addresses in this 

document, as of the date this document 

publishes in the Federal Register, but 

Web sites are subject to change over 

time. 

Transcripts: Please be advised that as 

soon as a transcript of the public 

workshop is available, it will be 

accessible at https://

www.regulations.gov. It may be viewed 

at the Dockets Management Staff (see 

ADDRESSES). A link to the transcript will 

also be available on the Internet at 

https://www.fda.gov/MedicalDevices/ 

NewsEvents/WorkshopsConferences/ 

default.htm. 

IV. References 

The following references are on 

display in the Dockets Management 

Staff (see ADDRESSES) and are available 

for viewing by interested persons 

between 9 a.m. and 4 p.m., Monday 

through Friday; they are also available 

electronically at https://

www.regulations.gov. FDA has verified 

the Web site addresses, as of the date 

this document publishes in the Federal 

Register, but Web sites are subject to 

change over time. 

1. National Cancer Institute, ‘‘Cancer Stat 

Facts: Cervix Uteri Cancer,’’ (http://

seer.cancer.gov/statfacts/html/ 

cervix.html). 

2. Horner, M.J., S.F. Altekruse, Z. Zou, L. 

Wideroff, et al. ‘‘U.S. Geographic 

Distribution of Pre-Vaccine Era Cervical 

Cancer Screening, Incidence, Stage, and 

Mortality.’’ Cancer Epidemiology, 

Biomarkers & Prevention. 2011 Jan.; 

20(4):591–9. doi: 10.1158/1055–9965. 

EPI–10–1183. 

3. Freeman, H.W.B. ‘‘Excess Cervical Cancer 

Mortality: A Marker for Low Access to 

Health Care in Poor Communities.’’ 

Rockville (MD): National Cancer 

Institute, Center to Reduce Cancer Health 

Disparities; 2005. 

Dated: September 1, 2017. 

Anna K. Abram, 

Deputy Commissioner for Policy, Planning, 

Legislation, and Analysis. 

[FR Doc. 2017–19029 Filed 9–7–17; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Heart, Lung, and Blood 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the NHLBI Special Emphasis 

Panel. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Heart, Lung, 

and Blood Institute Special Emphasis Panel; 

Resources for Clinical Trials. 

Date: September 20, 2017. 

Time: 11:00 a.m. to 1:00 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 6701 

Rockledge Drive, Room 7200, Bethesda, MD 

20892 (Telephone Conference Call). 

Contact Person: Michael P. Reilly, Ph.D., 

Scientific Review Officer, Office of Scientific 

Review/DERA, National Heart, Lung, and 

Blood Institute, 6701 Rockledge Drive, Room 

7200, Bethesda, MD 20892, 301–827–7975, 

reillymp@nhlbi.nih.gov. 

This notice is being published less than 15 

days prior to the meeting due to the timing 

limitations imposed by the review and 

funding cycle. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.233, National Center for 

Sleep Disorders Research; 93.837, Heart and 

Vascular Diseases Research; 93.838, Lung 

Diseases Research; 93.839, Blood Diseases 

and Resources Research, National Institutes 

of Health, HHS) 

Dated: September 1, 2017. 

Michelle Trout, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–19027 Filed 9–7–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; Pancreatic 

Cancer Detection Consortium (U01). 

Date: November 3, 2017. 

Time: 11:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Room 

7W240, Rockville, MD 20850, (Telephone 

Conferece Call). 

Contact Person: Hasan Siddiqui, Ph.D., 

Scientific Review Officer, Special Review 

Branch, Division of Extramural Activities, 

National Cancer Institute, NIH, 9609 Medical 

Center Drive, Room 7W240, Bethesda, MD 

20892–9750, 240–276–5122, hasan.siddiqui@

nih.gov. 

Name of Committee: National Cancer 

Institute Special Emphasis Panel; 

Cooperative Agreement To Develop Targeted 

Agents Used With Systemic Agents Plus 

Radiotherapy. 

Date: November 17, 2017. 

Time: 10:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute, Shady 

Grove, 9609 Medical Center Drive, Room 

7W640, Rockville, MD 20850, (Telephone 

Conferece Call). 

Contact Person: Saejeong J. Kim, Ph.D., 

Scientific Review Officer, Resources and 

Training Review Branch, Division of 

Extramural Activities, National Cancer 

Institute, NIH, 9609 Medical Center Drive, 

Room 7W640, Bethesda, MD 20892–9750, 

240–276–7684, saejeong.kim@nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: September 1, 2017. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–19026 Filed 9–7–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Proposed Collection; 30-Day Comment 

Request; Application To Participate in 

the National Institutes of Health 

Technical Assistance Programs: 

Commercialization Accelerator 

Program (CAP) 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 


sradovich on DSK3GMQ082PROD with NOTICES